These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30040081)

  • 1. Selection analyses of paired HIV-1 gag and gp41 sequences obtained before and after antiretroviral therapy.
    Tzou PL; Rhee SY; Pond SLK; Manasa J; Shafer RW
    Sci Data; 2018 Jul; 5():180147. PubMed ID: 30040081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors.
    Manasa J; Varghese V; Pond SLK; Rhee SY; Tzou PL; Fessel WJ; Jang KS; White E; Rögnvaldsson T; Katzenstein DA; Shafer RW
    Sci Rep; 2017 Sep; 7(1):11559. PubMed ID: 28912582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.
    Perrier M; Castain L; Regad L; Todesco E; Landman R; Visseaux B; Yazdanpanah Y; Rodriguez C; Joly V; Calvez V; Marcelin AG; Descamps D; Charpentier C
    J Antimicrob Chemother; 2019 Jun; 74(6):1679-1692. PubMed ID: 30768160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gp41 and Gag amino acids linked to HIV-1 protease inhibitor-based second-line failure in HIV-1 subtype A from Western Kenya.
    Coetzer M; Ledingham L; Diero L; Kemboi E; Orido M; Kantor R
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29098809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.
    Castain L; Perrier M; Charpentier C; Palich R; Desire N; Wirden M; Descamps D; Sayon S; Landman R; Valantin MA; Joly V; Peytavin G; Yazdanpanah Y; Katlama C; Calvez V; Marcelin AG; Todesco E
    J Antimicrob Chemother; 2019 Jul; 74(7):2019-2023. PubMed ID: 31050739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations.
    Banke S; Lillemark MR; Gerstoft J; Obel N; Jørgensen LB
    J Virol; 2009 Sep; 83(17):8916-24. PubMed ID: 19515784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.
    Larrouy L; Chazallon C; Landman R; Capitant C; Peytavin G; Collin G; Charpentier C; Storto A; Pialoux G; Katlama C; Girard PM; Yeni P; Aboulker JP; Brun-Vezinet F; Descamps D;
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2910-9. PubMed ID: 20439606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.
    Ghosn J; Delaugerre C; Flandre P; Galimand J; Cohen-Codar I; Raffi F; Delfraissy JF; Rouzioux C; Chaix ML
    PLoS One; 2011; 6(9):e24798. PubMed ID: 21949754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors?
    Kletenkov K; Hoffmann D; Böni J; Yerly S; Aubert V; Schöni-Affolter F; Struck D; Verheyen J; Klimkait T;
    J Antimicrob Chemother; 2017 Mar; 72(3):866-875. PubMed ID: 27999036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.
    Giandhari J; Basson AE; Coovadia A; Kuhn L; Abrams EJ; Strehlau R; Morris L; Hunt GM
    AIDS Res Hum Retroviruses; 2015 Aug; 31(8):776-82. PubMed ID: 25919760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of HIV-1 from patients with virological failure to a boosted protease inhibitor regimen.
    Lillemark MR; Gerstoft J; Obel N; Kronborg G; Pedersen C; Jørgensen LB; Madsen TV; Katzenstein TL
    J Med Virol; 2011 Mar; 83(3):377-83. PubMed ID: 21264856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.
    Ho SK; Perez EE; Rose SL; Coman RM; Lowe AC; Hou W; Ma C; Lawrence RM; Dunn BM; Sleasman JW; Goodenow MM
    AIDS; 2009 Aug; 23(13):1631-40. PubMed ID: 19625947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interplay of reverse transcriptase inhibitor therapy and gag p6 diversity in HIV type 1 subtype G and CRF02_AG.
    Ojesina AI; Chaplin B; Sankalé JL; Murphy R; Idigbe E; Adewole I; Ekong E; Idoko J; Kanki PJ
    AIDS Res Hum Retroviruses; 2008 Sep; 24(9):1167-74. PubMed ID: 18729771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients.
    Teto G; Nka AD; Fokam J; Bouba Y; Takou D; Fabeni L; Carioti L; Armenia D; Semengue ENJ; Dambaya B; Sosso SM; Colizzi V; Perno CF; Ceccherini-Silberstein F; Santoro MM; Ndjolo A
    Sci Rep; 2022 Jan; 12(1):1374. PubMed ID: 35082353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
    Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
    J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic diversity in the partial sequence of the HIV-1 gag gene among people living with multidrug-resistant HIV-1 infection.
    Alencar CS; Sabino EC; Diaz RS; Mendrone-Junior A; Nishiya AS
    Rev Inst Med Trop Sao Paulo; 2024; 66():e35. PubMed ID: 38865573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors.
    Knops E; Brakier-Gingras L; Schülter E; Pfister H; Kaiser R; Verheyen J
    Med Microbiol Immunol; 2012 May; 201(2):213-8. PubMed ID: 22200908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
    Larrouy L; Vivot A; Charpentier C; Bénard A; Visseaux B; Damond F; Matheron S; Chene G; Brun-Vezinet F; Descamps D;
    AIDS; 2013 Jan; 27(1):69-80. PubMed ID: 23018441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic analysis and natural polymorphisms in HIV-1 gp41 isolates from Maputo City, Mozambique.
    Ismael N; Bila D; Mariani D; Vubil A; Mabunda N; Abreu C; Jani I; Tanuri A
    AIDS Res Hum Retroviruses; 2014 Jun; 30(6):603-9. PubMed ID: 24188582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.
    Lambert-Niclot S; Flandre P; Malet I; Canestri A; Soulié C; Tubiana R; Brunet C; Wirden M; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2008 Nov; 62(5):905-8. PubMed ID: 18765410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.